{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:26:34Z","timestamp":1780917994606,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>KIF1A<\/jats:italic>\n                    -associated neurological disorder (KAND) is a genetic condition characterised by motor, cognitive and ophthalmologic features. The speech and language phenotype have not been systematically analysed. Here, we assess speech and language using observer- and clinician-reported outcomes, and performance outcome measures. 44 individuals (25 female) with KAND (median age 7 years, range 1\u201360 years) participated. Median age at diagnosis was 4 years (range 0.5\u201358 years).\n                    <jats:italic>KIF1A<\/jats:italic>\n                    variants were missense (41\/44 individuals, 93%), intragenic deletion (2\/44, 5%) and splice site (1\/44, 2%). Age at first words was delayed (&gt;12 months) in 38\/44 (86%) individuals. At assessment, 28\/44 (64%) combined words into sentences and all of the 20 individuals assessed had dysarthria. Apraxic speech features and phonological impairments occurred in children aged under 8 years. 36\/37 (97%) participants had language impairment, with expressive language skills stronger than receptive (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02) and written (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03) language on the Vineland Adaptive Behaviour Scales. 7\/32 (22%) caregivers reported speech and language regression. Mild to severe intellectual disability occurred in 31\/33 (94%) individuals. 22\/44 (50%) participants had used augmentative and alternative communication, such as key word sign or speech generating devices. Individuals had average social motivation skills in contrast to moderately impaired social cognition, communication and awareness on the Social Responsiveness Scale (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). 16\/44 (36%) had epilepsy and 40\/44 (91%) had visual impairment, namely nystagmus (16\/44, 36%), optic nerve atrophy and strabismus (both 12\/44, 27%). Individuals with KAND frequently have speech and language disorders necessitating early and targeted speech and language interventions.\n                  <\/jats:p>","DOI":"10.1038\/s41431-025-01867-0","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T11:20:48Z","timestamp":1747394448000},"page":"78-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Understanding speech and language in KIF1A-associated neurological disorder"],"prefix":"10.1038","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2822-6522","authenticated-orcid":false,"given":"Lottie D.","family":"Morison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3505-2631","authenticated-orcid":false,"given":"Adam P.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8431-0641","authenticated-orcid":false,"given":"John","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy A.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Verden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-5685","authenticated-orcid":false,"given":"Wendy K.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Braden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Bredebusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simranpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Scheffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-7405","authenticated-orcid":false,"given":"Angela T.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"1867_CR1","doi-asserted-by":"crossref","unstructured":"Boyle L, Rao L, Kaur S, Fan X, Mebane C, Hamm L, et al. Genotype and defects in microtubule-based motility correlate with clinical severity in KIF1A-associated neurological disorder. HGG Adv. 2021;2:100026.","DOI":"10.1016\/j.xhgg.2021.100026"},{"key":"1867_CR2","doi-asserted-by":"crossref","unstructured":"Abdelhakim AH, Brodie SE, Chung WK. Ophthalmic findings in the KIF1A-associated neurological disorder (KAND). Am J Ophthalmol. 2024;268:247\u201357.","DOI":"10.1016\/j.ajo.2024.06.025"},{"key":"1867_CR3","doi-asserted-by":"publisher","first-page":"101169","DOI":"10.1016\/j.gim.2024.101169","volume":"26","author":"KK Sudnawa","year":"2024","unstructured":"Sudnawa KK, Li W, Calamia S, Kanner CH, Bain JM, Abdelhakim AH, et al. Heterogeneity of comprehensive clinical phenotype and longitudinal adaptive function and correlation with computational predictions of severity of missense genotypes in KIF1A-associated neurological disorder. Genet Med. 2024;26:101169.","journal-title":"Genet Med"},{"key":"1867_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ajhg.2011.06.013","volume":"89","author":"JB Rivi\u00e8re","year":"2011","unstructured":"Rivi\u00e8re JB, Ramalingam S, Lavastre V, Shekarabi M, Holbert S, Lafontaine J, et al. KIF1A, an axonal transporter of synaptic vesicles, is mutated in hereditary sensory and autonomic neuropathy type 2. Am J Hum Genet. 2011;89:219\u201330.","journal-title":"Am J Hum Genet"},{"key":"1867_CR5","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1083\/jcb.119.5.1287","volume":"119","author":"H Aizawa","year":"1992","unstructured":"Aizawa H, Sekine Y, Takemura R, Zhang Z, Nangaku M, Hirokawa N. Kinesin family in murine central nervous system. J Cell Biol. 1992;119:1287\u201396.","journal-title":"J Cell Biol"},{"key":"1867_CR6","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0092-8674(95)90538-3","volume":"81","author":"Y Okada","year":"1995","unstructured":"Okada Y, Yamazaki H, Sekine-Aizawa Y, Hirokawa N. The neuron-specific kinesin superfamily protein KIF1A is a unique monomeric motor for anterograde axonal transport of synaptic vesicle precursors. Cell 1995;81:769\u201380.","journal-title":"Cell"},{"key":"1867_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/ejhg.2011.261","volume":"20","author":"S Klebe","year":"2012","unstructured":"Klebe S, Lossos A, Azzedine H, Mundwiller E, Sheffer R, Gaussen M, et al. KIF1A missense mutations in SPG30, an autosomal recessive spastic paraplegia: distinct phenotypes according to the nature of the mutations. Eur J Hum Genet. 2012;20:645\u20139.","journal-title":"Eur J Hum Genet"},{"key":"1867_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ajhg.2011.02.001","volume":"88","author":"FF Hamdan","year":"2011","unstructured":"Hamdan FF, Gauthier J, Araki Y, Lin DT, Yoshizawa Y, Higashi K, et al. Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. Am J Hum Genet. 2011;88:306\u201316.","journal-title":"Am J Hum Genet"},{"key":"1867_CR9","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/ejhg.2015.217","volume":"24","author":"S Langlois","year":"2016","unstructured":"Langlois S, Tarailo-Graovac M, Sayson B, Dr\u00f6gem\u00f6ller B, Swenerton A, Ross CJ, et al. De novo dominant variants affecting the motor domain of KIF1A are a cause of PEHO syndrome. Eur J Hum Genet. 2016;24:949\u201353.","journal-title":"Eur J Hum Genet"},{"key":"1867_CR10","doi-asserted-by":"publisher","first-page":"4446","DOI":"10.1093\/brain\/awad242","volume":"146","author":"KL Elvidge","year":"2023","unstructured":"Elvidge KL, Christodoulou J, Farrar MA, Tilden D, Maack M, Valeri M, et al. The collective burden of childhood dementia: a scoping review. Brain 2023;146:4446\u201355.","journal-title":"Brain"},{"key":"1867_CR11","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/humu.24079","volume":"41","author":"S Kaur","year":"2020","unstructured":"Kaur S, Van Bergen NJ, Verhey KJ, Nowell CJ, Budaitis B, Yue Y, et al. Expansion of the phenotypic spectrum of de novo missense variants in kinesin family member 1A (KIF1A). Hum Mutat. 2020;41:1761\u201374.","journal-title":"Hum Mutat"},{"key":"1867_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1055\/s-0039-3400988","volume":"51","author":"AE Van Beusichem","year":"2020","unstructured":"Van Beusichem AE, Nicolai J, Verhoeven J, Speth L, Coenen M, Willemsen MA, et al. Mobility characteristics of children with spastic paraplegia due to a mutation in the KIF1A gene. Neuropediatrics 2020;51:146\u201353.","journal-title":"Neuropediatrics"},{"key":"1867_CR13","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00415-021-10792-3","volume":"269","author":"SD Vecchia","year":"2022","unstructured":"Vecchia SD, Tessa A, Dosi C, Baldacci J, Pasquariello R, Antenora A, et al. Monoallelic KIF1A-related disorders: a multicenter cross sectional study and systematic literature review. J Neurol. 2022;269:437\u201350.","journal-title":"J Neurol"},{"key":"1867_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/jmedgenet-2020-107007","volume":"58","author":"F Nicita","year":"2021","unstructured":"Nicita F, Ginevrino M, Travaglini L, D\u2019Arrigo S, Zorzi G, Borgatti R, et al. Heterozygous KIF1A variants underlie a wide spectrum of neurodevelopmental and neurodegenerative disorders. J Med Genet. 2021;58:475\u201383.","journal-title":"J Med Genet"},{"key":"1867_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.parkreldis.2022.09.001","volume":"103","author":"SL Hsu","year":"2022","unstructured":"Hsu SL, Liao YC, Lin KP, Lin PY, Yu KW, Tsai YS, et al. Investigating KIF1A mutations in a Taiwanese cohort with hereditary spastic paraplegia. Parkinsonism Relat Disord. 2022;103:144\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"1867_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12999-9","volume":"7","author":"CK Cheon","year":"2017","unstructured":"Cheon CK, Lim SH, Kim YM, Kim D, Lee NY, Yoon TS, et al. Autosomal dominant transmission of complicated hereditary spastic paraplegia due to a dominant negative mutation of KIF1A, SPG30 gene. Sci Rep. 2017;7:12527.","journal-title":"Sci Rep"},{"key":"1867_CR17","doi-asserted-by":"crossref","unstructured":"Nair A, Greeny A, Rajendran R, Abdelgawad MA, Ghoneim MM, Raghavan RP, et al. KIF1A-associated neurological disorder: an overview of a rare mutational disease. Pharmaceuticals. 2023;16:147.","DOI":"10.3390\/ph16020147"},{"key":"1867_CR18","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.2169\/internalmedicine.1184-22","volume":"62","author":"K Nakamura","year":"2023","unstructured":"Nakamura K, Yoshinaga T, Kodaira M, Kise E, Kosho T, Sekijima Y. Long-term observation of a Japanese patient with a multiple-system neurodegenerative disorder with a uniallelic de novo missense variant in KIF1A. Intern Med. 2023;62:3047\u201351.","journal-title":"Intern Med"},{"key":"1867_CR19","doi-asserted-by":"crossref","unstructured":"Paprocka J, Jezela-Stanek A, \u015amigiel R, Walczak A, Mierzewska H, Kutkowska-Ka\u017amierczak A, et al. Expanding the knowledge of KIF1A-dependent disorders to a group of Polish patients. Genes. 2023;14:971.","DOI":"10.3390\/genes14050972"},{"key":"1867_CR20","doi-asserted-by":"crossref","unstructured":"Ziegler A, Carroll J, Bain JM, Sands TT, Fee RJ, Uher D, et al. Antisense oligonucleotide therapy in an individual with KIF1A-associated neurological disorder. Nat Med. 2024;30:2782\u20136.","DOI":"10.1038\/s41591-024-03197-y"},{"key":"1867_CR21","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1002\/humu.24118","volume":"41","author":"X Montenegro-Garreaud","year":"2020","unstructured":"Montenegro-Garreaud X, Hansen AW, Khayat MM, Chander V, Grochowski CM, Jiang Y, et al. Phenotypic expansion in KIF1A-related dominant disorders: a description of novel variants and review of published cases. Hum Mutat. 2020;41:2094\u2013104.","journal-title":"Hum Mutat"},{"key":"1867_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41431-022-01230-7","volume":"31","author":"M St John","year":"2023","unstructured":"St John M, van Reyk O, Koolen DA, de Vries BB, Amor DJ, Morgan AT. Expanding the speech and language phenotype in Koolen-de Vries syndrome: late onset and periodic stuttering a novel feature. Eur J Hum Genet. 2023;31:531\u201340.","journal-title":"Eur J Hum Genet"},{"key":"1867_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/jmg-2023-109702","volume":"61","author":"LD Morison","year":"2024","unstructured":"Morison LD, Kennis MGP, Rots D, Bouman A, Kummeling J, Palmer E, et al. Expanding the phenotype of Kleefstra syndrome: speech, language and cognition in 103 individuals. J Med Genet. 2024;61:578\u201385.","journal-title":"J Med Genet"},{"key":"1867_CR24","doi-asserted-by":"crossref","unstructured":"Forbes EJ, Morison LD, Lelik F, Howell T, Debono S, Goel H, et al. Speech and language in DDX3X-neurodevelopmental disorder: a call for early augmentative and alternative communication intervention. Am J Med Genet B Neuropsychiatr Genet. 2024;195:e32971.","DOI":"10.1002\/ajmg.b.32971"},{"key":"1867_CR25","doi-asserted-by":"publisher","first-page":"e12838","DOI":"10.1002\/jimd.12838","volume":"48","author":"LD Morison","year":"2025","unstructured":"Morison LD, Whiteman IT, Vogel AP, Tilbrook L, Fahey MC, Braden R, et al. Speech, language and non-verbal communication in CLN2 and CLN3 Batten disease. J Inherit Metab Dis. 2025;48:e12838.","journal-title":"J Inherit Metab Dis"},{"key":"1867_CR26","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","DOI":"10.1001\/jama.2013.281053"},{"key":"1867_CR27","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41431-021-00894-x","volume":"29","author":"A Morgan","year":"2021","unstructured":"Morgan A, Braden R, Wong MM, Colin E, Amor D, Li\u00e9geois F, et al. Speech and language deficits are central to SETBP1 haploinsufficiency disorder. Eur J Hum Genet. 2021;29:1216\u201325.","journal-title":"Eur J Hum Genet"},{"key":"1867_CR28","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/apa.14299","volume":"107","author":"BF Pados","year":"2018","unstructured":"Pados BF, Thoyre SM, Park J. Age\u2010based norm\u2010reference values for the Child Oral and Motor Proficiency Scale. Acta Paediat. 2018;107:1427\u201332.","journal-title":"Acta Paediat"},{"key":"1867_CR29","volume-title":"Motor speech disorders: substrates, differential diagnosis, and management, 5th ed","author":"JR Duffy","year":"2019","unstructured":"Duffy JR. Motor speech disorders: substrates, differential diagnosis, and management, 5th ed. Elsevier; 2019."},{"key":"1867_CR30","unstructured":"ASHA. Childhood apraxia of speech technical report 2007. 2024. Available from: https:\/\/www.asha.org\/policy\/tr2007-00278\/."},{"key":"1867_CR31","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41431-018-0102-x","volume":"26","author":"C Mei","year":"2018","unstructured":"Mei C, Fedorenko E, Amor DJ, Boys A, Hoeflin C, Carew P, et al. Deep phenotyping of speech and language skills in individuals with 16p11. 2 deletion. Eur J Hum Genet. 2018;26:676\u201386.","journal-title":"Eur J Hum Genet"},{"key":"1867_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40474-014-0017-3","volume":"1","author":"B Dodd","year":"2014","unstructured":"Dodd B. Differential diagnosis of pediatric speech sound disorder. Curr Dev Disord Rep. 2014;1:189\u201396.","journal-title":"Curr Dev Disord Rep"},{"key":"1867_CR33","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1044\/1092-4388(2011\/10-0130)","volume":"55","author":"S McLeod","year":"2012","unstructured":"McLeod S, Harrison LJ, McCormack J. The intelligibility in context scale: validity and reliability of a subjective rating measure. J Speech Lang Hear Res. 2012;55:648\u201356.","journal-title":"J Speech Lang Hear Res"},{"key":"1867_CR34","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1212\/WNL.0000000000009776","volume":"95","author":"AP Vogel","year":"2020","unstructured":"Vogel AP, Magee M, Torres-Vega R, Medrano-Montero J, Cyngler MP, Kruse M, et al. Features of speech and swallowing dysfunction in pre-ataxic spinocerebellar ataxia type 2. Neurology 2020;95:e194\u2013e205.","journal-title":"Neurology"},{"key":"1867_CR35","unstructured":"Sparrow S, Cicchetti, D., Saulnier, C. Vineland adaptive behavior scales, 3rd ed. San Antonio, TX: Pearson Assessments; 2016."},{"key":"1867_CR36","volume-title":"Vineland adaptive behavior scales","author":"SS Sparrow","year":"2005","unstructured":"Sparrow SS, Cicchetti DV, Balla DA. Vineland adaptive behavior scales. second edition. Circle Pines, MN: American Guidance Service; 2005.","edition":"second edition"},{"key":"1867_CR37","unstructured":"Bishop DV, Cubero NS. Children\u2019s communication checklist, 2nd ed. London: PsychCorp.; 2003."},{"key":"1867_CR38","unstructured":"Rowland C. Communication matrix. Portland, OR: Oregon Health & Science University; 2004."},{"key":"1867_CR39","unstructured":"Constantino J, Gruber C. Social responsiveness scale, 2nd ed. Torrance, CA.: Western Psychological Services; 2012."},{"key":"1867_CR40","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association D, American Psychiatric Association D. Diagnostic and statistical manual of mental disorders: DSM-5. Washington, DC: American psychiatric association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"1867_CR41","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/13682820903461493","volume":"45","author":"K Hudry","year":"2010","unstructured":"Hudry K, Leadbitter K, Temple K, Slonims V, McConachie H, Aldred C, et al. Preschoolers with autism show greater impairment in receptive compared with expressive language abilities. Int J Lang Commun Disord. 2010;45:681\u201390.","journal-title":"Int J Lang Commun Disord"},{"key":"1867_CR42","doi-asserted-by":"crossref","unstructured":"Rao L, Li W, Shen Y, Chung WK, Gennerich A. Distinct clinical phenotypes in KIF1A-associated neurological disorders result from different amino acid substitutions at the same residue in KIF1A. bioRxiv. 2025. https:\/\/www.biorxiv.org\/content\/10.1101\/2025.02.26.640415v1?med=mas.","DOI":"10.1101\/2025.02.26.640415"},{"key":"1867_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3109\/07434618.2016.1146331","volume":"32","author":"MC Therrien","year":"2016","unstructured":"Therrien MC, Light J, Pope L. Systematic review of the effects of interventions to promote peer interactions for children who use aided AAC. Augment Alternat Commun. 2016;32:81\u201393.","journal-title":"Augment Alternat Commun"},{"key":"1867_CR44","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3109\/17483107.2013.769122","volume":"8","author":"T Iacono","year":"2013","unstructured":"Iacono T, Lyon K, Johnson H, West D. Experiences of adults with complex communication needs receiving and using low tech AAC: an Australian context. Disabil Rehabilit Assist Technol. 2013;8:392\u2013401.","journal-title":"Disabil Rehabilit Assist Technol"},{"key":"1867_CR45","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/00001163-200507000-00002","volume":"18","author":"M Romski","year":"2005","unstructured":"Romski M, Sevcik RA. Augmentative communication and early intervention: myths and realities. Infants Young Child. 2005;18:174\u201385.","journal-title":"Infants Young Child"},{"key":"1867_CR46","doi-asserted-by":"crossref","unstructured":"Brittlebank S, Light JC, Pope L. A scoping review of AAC interventions for children and young adults with simultaneous visual and motor impairments: Clinical and research Implications. Augment Altern Commun. 2024;40:219\u2013237.","DOI":"10.1080\/07434618.2024.2327044"},{"key":"1867_CR47","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1044\/2021_AJSLP-20-00203","volume":"30","author":"JB Boster","year":"2021","unstructured":"Boster JB, McCarthy JW, Brown K, Spitzley AM, Blackstone SW. Creating a path for systematic investigation of children with cortical visual impairment who use augmentative and alternative communication. Am J Speech-Lang Pathol. 2021;30:1880\u201393.","journal-title":"Am J Speech-Lang Pathol"},{"key":"1867_CR48","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.pmr.2012.06.003","volume":"23","author":"LJ Ball","year":"2012","unstructured":"Ball LJ, Fager S, Fried-Oken M. Augmentative and alternative communication for people with progressive neuromuscular disease. Phys Med Rehabilit Clin. 2012;23:689\u201399.","journal-title":"Phys Med Rehabilit Clin."},{"key":"1867_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000287207","volume":"62","author":"J Folker","year":"2010","unstructured":"Folker J, Murdoch B, Cahill L, Delatycki M, Corben L, Vogel A. Dysarthria in Friedreich\u2019s ataxia: a perceptual analysis. Folia Phoniatr Logop. 2010;62:97\u2013103.","journal-title":"Folia Phoniatr Logop"},{"key":"1867_CR50","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s12311-022-01435-y","volume":"22","author":"KH Kenyon","year":"2023","unstructured":"Kenyon KH, Boonstra F, Noffs G, Butzkueven H, Vogel AP, Kolbe S, et al. An update on the measurement of motor cerebellar dysfunction in multiple sclerosis. Cerebellum 2023;22:761\u201375.","journal-title":"Cerebellum"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01867-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:09:47Z","timestamp":1768810187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01867-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1867"],"URL":"https:\/\/doi.org\/10.1038\/s41431-025-01867-0","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"2 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DV is the Research Engagement Director at KIF1A.org. APV is the Chief Science Officer and ATM is the director of paediatric\/neurodevelopment communication at Redenlab Pty Ltd. JC is a member of the Anavex Drug Safety and Monitoring Board for a Rett syndrome drug trial and is not in receipt of any remuneration for this involvement. JC is an expert advisor for Taysha Gene Therapies which is running a Rett syndrome gene therapy trial and is receiving remuneration for this involvement. IES is a consultant for Biohaven Pharmaceuticals, Care Beyond Diagnosis, Cerecin Inc, Eisai, Epilepsy Consortium, Longboard Pharmaceuticals, UCB, Zynerba Pharmaceuticals. IES has received payment honoraria and travel support from Biocodex, BioMarin, Chiesi, Eisai, GlaxoSmithKline, Liva Nova, Nutricia, Stoke Therapeutics, UCB, Zuellig Pharma. IES is on scientific advisory boards for Bellberry Ltd, BioMarin, Chiesi, Eisai, Encoded Therapeutics, Garvan Institute of Medical Research, Knopp Biosciences, Longboard Pharmaceuticals, UCB, Takeda Pharmaceuticals. IES is a director at Bellberry Ltd, Australian Academy of Health and Medical Sciences, Australian Council of Learned Academies Ltd. IES is a trial investigator for Anavex Life Sciences, Cerebral Therapeutics, Cerecin Inc, Cereval Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, ES-Therapeutics, GW Pharmaceuticals, Marinus Pharmaceuticals, Neuren Pharmaceuticals, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix, Zynerba Pharmaceuticals. IES has a patent issued for # Molecular diagnostic\/theranostic target for benign familial infantile epilepsy (BFIE) [PRRT2] 2011904493 & 2012900190 and PCT\/AU2012\/001321 (TECH ID:2012-009)\n                      # SCN1A\n                      testing held by Bionomics Inc and a patent pending for WO61\/010176 (filed: 2008): Therapeutic Compound. All other authors have no competing interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was obtained from the Royal Children\u2019s Hospital Human Research Ethics Committee (HREC 37353A), Columbia University and Boston Children\u2019s Hospital institutional review boards. All participants\/caregivers provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}